Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

SWOG S0120 Observational Trial for MGUS and Asymptomatic Multiple Myeloma (AMM): Imaging Predictors of Progression for Patients Treated At UAMS,

Christoph Heuck, MD, Rachael Sexton, Madhav Dhodapkar, MD, MBBS, Qing Zhang, PhD, Saad Usmani, MD, FACP, Bijay Nair, MD, Frits van Rhee, MD, PhD, Antje Hoering, PhD, John Crowley, PhD, John D Shaughnessy, Jr., PhD, Robert Z. Orlowski, MD, PhD, Bart Barlogie, MD, PhD

Blood (2011) 118 (21): 3955.

https://doi.org/10.1182/blood.V118.21.3955.3955

Published: 2011

Journal Articles

Predicting Disease Progression to Multiple Myeloma (MM) From MGUS/SMM In SWOG-0120 Observational Trial

Madhav Dhodapkar, MD, MBBS, John Shaughnessy, Jr, PhD, Antje Hoering, PhD, Bijay Nair, MD, MPH, Vanessa Bolejack, Frits van Rhee, MD, PhD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2010) 116 (21): 1932.

https://doi.org/10.1182/blood.V116.21.1932.1932

Published: 2010

Journal Articles

Risk-Adapted Dosing of Melphalan for Systemic AL Amyloidosis (AL) Lowers Treatment-Related Mortality: Early Death but Not Post-3 Month Survival Is Linked to Cardiac Involvement.

Raymond L. Comenzo, MD, Ping Zhou, MD, PhD, Hani Hassoun, MD, Tarun Kewalramani, MD, Virginia Klimek, MD, Adam D. Cohen, MD, Susane K. Ferrand, MD, Madhav Dhodapkar, MD, Julie Teruya-Feldstein, MD, Martin Fleisher, PhD, Stephen D. Nimer, MD

Blood (2005) 106 (11): 1156.

https://doi.org/10.1182/blood.V106.11.1156.1156

Published: 2005

Journal Articles

The Serum Free Light Chain Ratio after One or Two Cycles of Treatment Is Highly Predictive of the Magnitude of Final Response in Patients Undergoing Initial Treatment for Multiple Myeloma.

Hani Hassoun, MD, Lilian Reich, MD, Virginia M. Klimek, MD, Madhav Dhodapkar, MD, Adam Cohen, MD, Tarun Kewalramani, MD, Elyn R. Riedel, MA, Cyrus V. Hedvat, MD, Julie Teruya-Feldstein, MD, Daniel A. Filippa, MD, Martin Fleisher, PhD, Stephen D. Nimer, MD, Raymond L. Comenzo, MD

Blood (2005) 106 (11): 3481.

https://doi.org/10.1182/blood.V106.11.3481.3481

Published: 2005

Journal Articles

Doxorubicin and Dexamethasone Followed by Thalidomide and Dexamethasone (AD-TD) as Initial Therapy for Symptomatic Patients with Multiple Myeloma.

Hani Hassoun, MD, Lilian Reich, MD, Virginia M. Klimek, MD, Tarun Kewalramani, MD, Madhav Dhodapkar, MD, Lisa Drake, Rachel Zimman, Cyrus V. Hedvat, MD, Teruya-Feldstein Julie, MD, Fleisher Martin, phD, Daniel A. Filippa, MD, Stephen D. Nimer, MD, Raymond L. Comenzo, MD

Blood (2004) 104 (11): 2409.

https://doi.org/10.1182/blood.V104.11.2409.2409

Published: 2004

NARROW

SWOG S0120 Observational Trial for MGUS and Asymptomatic Multiple Myeloma (AMM): Imaging Predictors of Progression for Patients Treated At UAMS,

Predicting Disease Progression to Multiple Myeloma (MM) From MGUS/SMM In SWOG-0120 Observational Trial

Risk-Adapted Dosing of Melphalan for Systemic AL Amyloidosis (AL) Lowers Treatment-Related Mortality: Early Death but Not Post-3 Month Survival Is Linked to Cardiac Involvement.

The Serum Free Light Chain Ratio after One or Two Cycles of Treatment Is Highly Predictive of the Magnitude of Final Response in Patients Undergoing Initial Treatment for Multiple Myeloma.

Doxorubicin and Dexamethasone Followed by Thalidomide and Dexamethasone (AD-TD) as Initial Therapy for Symptomatic Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

SWOG S0120 Observational Trial for MGUS and Asymptomatic Multiple Myeloma (AMM): Imaging Predictors of Progression for Patients Treated At UAMS,

Predicting Disease Progression to Multiple Myeloma (MM) From MGUS/SMM In SWOG-0120 Observational Trial

Risk-Adapted Dosing of Melphalan for Systemic AL Amyloidosis (AL) Lowers Treatment-Related Mortality: Early Death but Not Post-3 Month Survival Is Linked to Cardiac Involvement.

The Serum Free Light Chain Ratio after One or Two Cycles of Treatment Is Highly Predictive of the Magnitude of Final Response in Patients Undergoing Initial Treatment for Multiple Myeloma.

Doxorubicin and Dexamethasone Followed by Thalidomide and Dexamethasone (AD-TD) as Initial Therapy for Symptomatic Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only